Diabete Mellitus, Diabete Type 2, Hyperglycaemia (Diabetic)
Conditions
Brief summary
This was a prospective, observational cross-sectional study conducted at a tertiary care private hospital in India. The study was designed to comprehensively evaluate the prevalence, management strategies, and clinical outcomes of in-hospital hyperglycemia among adult inpatients. The study also explored the associations of metabolic biomarkers-fetuin-A and fibroblast growth factor-21 (FGF-21) as well as sarcopenic obesity and nutritional factors with clinical outcomes, including length of hospital stay (LOS), complications, and mortality. Institutional Ethics Committee approval was obtained prior to study initiation, and written informed consent was secured from all participants
Interventions
None listed
Sponsors
Medanta, The Medicity, India
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients aged ≥18 years. * Patients with known or newly diagnosed type 2 diabetes mellitus (T2DM) or those presenting with hyperglycemia (random blood glucose ≥140 mg/dL) during hospitalization. * Both medical and surgical inpatients admitted for ≥24 hours
Exclusion criteria
* Pregnant or lactating women. * Patients with type 1 diabetes mellitus or other specific types of diabetes (e.g., pancreatogenic, drug-induced). * Patients with chronic liver disease unrelated to diabetes or hepatic dysfunction secondary to viral hepatitis, autoimmune hepatitis, or alcohol abuse. * Critically ill patients requiring palliative care or those with advanced malignancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To determine the prevalence of hyperglycemia | 10 Days | To determine the prevalence of hyperglycemia and pre-existing or newly diagnosed type 2 diabetes mellitus (T2DM) among hospitalized patients |
| Assess clinical outcomes associated with hyperglycemia | 10 Days | To assess clinical outcomes associated with hyperglycemia, including in-hospital complications, mortality, need for critical care support, and length of hospital stay (LOS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of sarcopenic obesity | 10 Days | To assess the prevalence of sarcopenic obesity among diabetic and hyperglycemic patients, and to determine its association with metabolic dysfunction and adverse outcomes |
| Analyze serum biomarker level fetuin-A | 10 Days | To analyze serum biomarker level fetuin-A and correlate them with severity of metabolic dysregulation .Serum fetuin-A levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits |
| Analyze serum biomarker level FGF-21 | 10 Days | To analyze serum biomarker levels FGF-21 and correlate them with severity of metabolic dysregulation.Serum FGF-21 levels were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits |
| To assess Impact of diet | 10 Days | To assess the impact of adequacy of dietary on glycemic control and recovery, will measure the Sugar level at Before Breakfast,Before Lunch,Before Dinner |
Countries
India
Outcome results
None listed